SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com), today announced that Richard Pascoe, Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference, being held at The Waldorf Astoria in New York City. Mr. Pascoe's presentation will take place on Tuesday, February 11, 2014 at 9:30 a.m. Eastern Time.
The presentation will be webcast and accessible to the public online at http://www.veracast.com/webcasts/bio/ceoinvestor2014/18225148879.cfm or via the Company's website at http://www.apricusbio.com. A replay will be available for 90 days after the presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and markets through its licensing partners innovative treatments that have the potential to help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros®, for the treatment of erectile dysfunction, which is now approved in Europe and Canada and will be commercialized by Apricus' marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Bracco SpA and Laboratoires Majorelle. Femprox®, the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed a nearly 400-subject proof-of-concept study.
For further information on Apricus, visit http://www.apricusbio.com.
CONTACT: Apricus Investor Relations: David Pitts or Lourdes Catala Argot Partners 212-600-1902 email@example.com firstname.lastname@example.org
|Regado Biosciences to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/4)|
|Trevena to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/4)|
|Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/3)|
|Transition Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/6)|
|Ohr Pharmaceutical to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/4)|
|ZIOPHARM Oncology to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/3)|
|Prima BioMed to Present at the 16th Annual BIO CEO & Investor Conference (2014/1/30)|
|Targacept to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/4)|
|La Jolla Pharmaceutical Company to Present at the 16th Annual BIO CEO & Investor Conference (2014/2/5)|
|Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City (2014/2/5)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.